Tokyo, Sept. 24 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000063029) titled 'An observational study to evaluate the clinical utility of dosimetry in lutetium-177 radionuclide therapy' on Sept. 24.
Study Type:
Observational
Primary Sponsor:
Institute - Keio University School of Medicine
Condition:
Condition - Patients who received Lu-177-labeled radionuclide therapy
Classification by malignancy - Malignancy
Genomic information - NO
Objective:
Narrative objectives1 - In patients who received Lu-177-labeled radionuclide therapy, we will perform dosimetry of tumors and organs based on post-administration tracer uptake measured with SPECT, and evaluate the association of the absorbed doses with treatment response and the occurrence of adverse events.
Basic objectives2 - Safety,Efficacy
Eligibility:
Age-lower limit - Not applicable
Age-upper limit - Not applicable
Gender - Male and Female
Key inclusion criteria - Patients scheduled to receive Lu-177-labeled radionuclide therapy who provide written informed consent to participate in this study.
Key exclusion criteria - 1) Minors
2) Patients who did not provide consent to participate in this study
3) Patients judged by the principal investigator or other investigators to be ineligible for this study
Target Size - 250
Recruitment Status:
Recruitment status - Preinitiation
Date of protocol fixation - 2026 Year 04 Month 28 Day
Anticipated trial start date - 2026 Year 11 Month 01 Day
Last follow-up date - 2035 Year 03 Month 31 Day
To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000072154
Disclaimer: Curated by HT Syndication.
